Home > Resources > Whitepapers > The A to Z of microarrays evolution of a revolutionary solution

Cell and Gene Therapy, Medical

The A to Z of microarrays evolution of a revolutionary solution

May 27, 2023

The Human Genome Project was a monumental effort over more than a decade to determine the human DNA sequence and analyze genetic variation among individuals. The hope was that, armed with this understanding, phenotypic differences would be explainable by genetic variation, and health benefits could follow.

Spotlight

SCIENION

SCIENION is a German company (based in Berlin and Dortmund) with a subsidiary in the US (in Princeton, NJ). The company offers complete solutions for parallel bioanalytics and high throughput production/screening of microarrays in genomics and proteomics.

OTHER WHITEPAPERS

The US Bioeconomy

whitePaper | April 14, 2022

In the nearly 50 years since the first genetic engineering experiments, the United States has become the world’s biotechnology powerhouse,

Risk assessment of fungal materials

whitePaper | February 24, 2022

Sustainable fungal materials have a high potential to replace non-sustainable materials such as those used for packaging or as an alternative for leather and textile.

U.S. Biopharma Expansions to Europe: Ensuring Successful Build-Out & Market Access

whitePaper | May 24, 2023

The Greater Zurich Area Ltd (GZA), Apellis, and Korn Ferry co-hosted a virtual roundtable for a select group of biopharma leaders interested in expanding their operations into Europe. The panel brought together European launch specialists, talent experts, and Swiss government officials to cover critical questions and guiding principles necessary for a successful European launch, as well as insider knowledge of how to best navigate the regulatory environment.

BLOCKCHAIN ENABLED GENOME SECURITY FROM THE MOMENT IT IS SEQUENCED

whitePaper | June 8, 2022

Sequencing of human genomes is fast becoming an affordable technology for general consumer.

Bispecific Antibodies - CMC Considerations

whitePaper | December 16, 2022

Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding domains.

The affordability hurdle for gene therapies

whitePaper | October 12, 2022

Advanced therapy medicinal products cell and gene therapies offer tremendous hope for patients either by actually curing serious diseases or by alleviating suffering.